An embodiment of the present invention is directed to a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines comprising: a protein carrier comprising an inserted nucleic acid consensus sequence at least one polysaccharide such as a capsular Gram-positive polysaccharide linked to the consensus sequence and, optionally, an adjuvant or pharmaceutically acceptable carrier. In a further aspect, the instant invention is directed to methods of producing Gram-positive and other bioconjugate vaccines. In another aspect, an N-glycosylated protein is provided that comprises one or more polysaccharides such as Gram-positive polysaccharides. The present invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine. Further, the invention is directed to methods of inducing an immune response in a mammal comprising administering said bioconjugate vaccines.Un mode de réalisation de la présente invention concerne un nouveau vaccin bioconjugué de S. aureus. Plus généralement, linvention concerne des vaccins bioconjugués Gram positif et autres comprenant : un vecteur protéique comprenant une séquence consensus dacide nucléique insérée au moins un polysaccharide tel quun polysaccharide Gram positif capsulaire lié à la séquence consensus et, facultativement, un adjuvant ou un vecteur pharmaceutiquement acceptable. Dans un autre aspect, la présente invention concerne des procédés de production de vaccins bioconjugués Gram positif et autres. Dans un autre aspect, une protéine N-glycosylée est décrite qui comprend un ou plusieurs polysaccharides tels que des polysa
